The initiation of coverage by a major financial institution like Goldman Sachs generally brings increased attention to a stock. However, the Neutral rating suggests that Goldman Sachs views DVAX as fairly valued at its current price, implying limited short-term price movement. The price target of $20 provides a reference point for investors but does not suggest significant upside or downside, hence the neutral impact score.